The bepirovirsen market is forecast to grow from USD 266.13 million in 2027, its first full year of commercial sales, to USD 2,116.99 million by 2035, a compound annual growth rate (CAGR) of 29.6%, according to Acumen Research and Consulting. Launch-year revenue in 2026 is estimated at USD 36.04 million, and North America is expected to account for almost three-quarters of sales at the outset.
Those projections now rest on firmer ground. On 20 October 2026, GSK and Ionis announced that the US Food and Drug Administration (FDA) had approved bepirovirsen, sold as Hibsago, for adults with chronic hepatitis B. Japan approved it in August. For a disease where today’s pills suppress the virus but almost never clear it, a six-month treatment that can lead to a functional cure in some patients changes how doctors, payers and investors think about the field.
The Numbers in Brief
| Metric | Value |
|---|---|
| Estimated revenue, 2026 (launch year) | USD 36.04 million |
| Market size, 2027 | USD 266.13 million |
| Market size, 2035 | USD 2,116.99 million |
| CAGR, 2027 to 2035 | 29.6% |
| Largest region, 2027 | North America (73.86%) |
| Fastest-growing region | Europe (52.7% CAGR) |
| Largest distribution channel | Specialty pharmacies (48% in 2027) |
Data: Acumen Research and Consulting, Bepirovirsen Market report, updated 23 October 2026.
What Is Bepirovirsen?
Bepirovirsen is an antisense oligonucleotide, a short strand of synthetic genetic material designed to bind hepatitis B virus (HBV) RNA. By doing so, it reduces the production of viral proteins, most importantly hepatitis B surface antigen (HBsAg). HBsAg is thought to help the virus dampen the immune response, so lowering it may allow the body to regain control of the infection. Ionis Pharmaceuticals discovered the drug, and GSK holds the rights to develop and sell it.
It is not a replacement for existing antivirals. Patients take it alongside the nucleos(t)ide analogue tablets, such as tenofovir or entecavir, that most people with chronic hepatitis B already use. Treatment lasts six months, with injections under the skin given at home after the first dose.
Why a Functional Cure Changes the Commercial Picture
Current hepatitis B treatment is effective but open-ended. Nucleos(t)ide analogues keep the virus suppressed, yet fewer than 1% of patients achieve a functional cure after a year of standard care. Most stay on daily pills for life.
A functional cure means that both HBV DNA and HBsAg remain undetectable for at least 24 weeks after all treatment stops. In the pooled Phase III B-Well 1 and B-Well 2 trials, 19% of eligible patients treated with bepirovirsen reached that goal (233 of 1,220), compared with none on placebo. Among patients with a baseline HBsAg level of 1,000 IU/mL or lower, the rate rose to 26%.
Those figures explain the market’s shape. A finite, high-value course of therapy behaves very differently from a cheap generic pill taken for decades. Revenue depends less on how long patients stay on treatment and more on how many eligible people can be found, tested and treated. That makes diagnosis, not prescribing habits, the real bottleneck.
Who Qualifies for Treatment?
The US label is deliberately narrow. Bepirovirsen is approved for adults who:
- have chronic hepatitis B without cirrhosis,
- have been on nucleos(t)ide analogue therapy for at least six months,
- have suppressed HBV DNA, and
- have a baseline HBsAg level of 3,000 IU/mL or lower, confirmed by an FDA-authorised quantitative test.
The last requirement matters most commercially. Quantitative HBsAg testing is not yet routine everywhere, so every new prescription depends on a lab result many patients have never had.
How the Bepirovirsen Market Breaks Down
By baseline HBsAg level
Patients with HBsAg between 100 and 1,000 IU/mL are expected to form the largest group, at 38% of the market in 2027, rising to 39% by 2035. The segment between 1,000 and 3,000 IU/mL is projected to grow fastest, at a 32.1% CAGR, increasing from 30% to 35% of the market. Those with the lowest levels (100 IU/mL or below) make up 32% in 2027.
By HBeAg status
HBeAg-negative patients dominate, accounting for 84% of 2027 revenue. This reflects the real-world population: most adults on long-term antiviral therapy are HBeAg-negative. The HBeAg-positive group is smaller but expected to grow slightly faster, at a 31.5% CAGR.
By distribution channel and end user
Specialty pharmacies are expected to handle 48% of sales in 2027 and 52% by 2035, which is typical for an injectable therapy that requires lab monitoring. Retail and online pharmacies are the fastest-growing channel, with a projected 33.3% CAGR. Hospital hepatology and gastroenterology centres account for 58% of 2027 demand, but community health centres are expanding fastest, at a 36.3% CAGR. That shift suggests treatment will gradually move out of tertiary centres as clinicians grow familiar with the drug.
Regional Outlook: Where Will Bepirovirsen Sell?
| Region | Share, 2027 | Share, 2035 | Status |
|---|---|---|---|
| North America | 73.86% | 46.42% | Approved in the US (October 2026) |
| Japan | 16.09% | 8.61% | Approved (August 2026) |
| Europe | 6.76% | 25.10% | Under regulatory review |
| China | 3.29% | 9.94% | Under regulatory review |
| Rest of Asia-Pacific, Latin America, Middle East and Africa | 0% | about 10% combined | Future launches |
North America leads at launch
The US is the first large market with full approval and established specialty pharmacy networks. Around 1.7 million people live with chronic hepatitis B in the country, and North America’s revenue is projected to grow from USD 196.56 million in 2027 to USD 982.80 million by 2035. Its share falls over time only because other regions catch up.
Japan moves early
Japan approved bepirovirsen on 24 August 2026, ahead of the US. With about 1 million people living with chronic hepatitis B and a well-organised hepatology system, it is expected to contribute 16% of revenue in 2027.
Europe is the fastest-growing region
Europe’s share is forecast to climb from under 7% to about 25%, with revenue rising from USD 17.99 million to USD 531.32 million, a 52.7% CAGR. That growth depends on regulatory approval, which GSK expects in the coming months, followed by country-by-country pricing and reimbursement negotiations.
China holds the largest long-term opportunity
China has the world’s largest hepatitis B population. Its regulator accepted the bepirovirsen application in March 2026 and granted it priority review, and GSK signed a strategic collaboration with Sino Biopharmaceutical in May 2026 to develop and commercialise the drug locally. Acumen projects China’s revenue rising from USD 8.75 million in 2027 to USD 210.36 million by 2035.
What about India?
Bepirovirsen is not yet approved in India, and no filing has been announced. India carries one of the larger hepatitis B burdens in Asia, so the eventual opportunity is significant. Pricing, the availability of quantitative HBsAg testing outside major cities, and the need for weekly platelet monitoring will decide how quickly that opportunity can be reached.
Competitive Landscape
For now, bepirovirsen has the functional-cure field to itself. No other therapy designed to achieve a functional cure of hepatitis B is approved. That lead may not last forever, though, because several companies are developing therapies with the same goal:
| Company | Candidate | Approach |
|---|---|---|
| GSK and Ionis Pharmaceuticals | Bepirovirsen (Hibsago) | Antisense oligonucleotide (approved) |
| Aligos Therapeutics | ALG-000184 and ALG-170675 | Oral capsid assembly modulator; antisense oligonucleotide |
| Arrowhead Pharmaceuticals and Janssen | JNJ-3989 (ARO-HBV) | RNA interference |
| Arbutus Biopharma | AB-729 | RNA interference |
Rather than simply competing, these approaches may end up working together. Researchers widely expect the next step to be combination regimens, in which an HBsAg-lowering drug is paired with an immune-boosting agent to raise cure rates beyond what one drug can achieve alone. If that happens, bepirovirsen’s early clinical experience could make it the backbone of future combinations.
What Could Slow Adoption?
Bepirovirsen’s label comes with a boxed warning and several precautions that will shape real-world use:
- Liver flares: Sharp rises in liver enzymes can occur, mostly in the first 12 weeks, which is why patients with cirrhosis are excluded.
- Low platelet counts: Thrombocytopenia can be sudden and serious, so platelets must be checked at least weekly during treatment.
- Kidney and immune effects: Declines in kidney function and inflammatory reactions require ongoing laboratory monitoring.
- Patient identification: Finding patients who meet every eligibility criterion takes time, testing and specialist input.
- Response varies: Most treated patients do not achieve a functional cure, and results depend heavily on baseline HBsAg levels.
- Price and reimbursement: No launch price has been disclosed, and payer decisions will strongly influence uptake, especially outside the US.
None of these are unusual for a first-in-class therapy, but together they mean early sales will grow steadily rather than explosively. Hospitals that build simple referral and monitoring pathways are likely to be the first to treat patients at scale.
Our Take: Testing Will Decide the Pace
The most important number in this market may not be the cure rate but the testing rate. The World Health Organization estimates that more than 250 million people live with chronic hepatitis B worldwide, yet only a small fraction are diagnosed, and fewer still have had a quantitative HBsAg test. Every expansion in testing directly enlarges the pool of people who could benefit from bepirovirsen.
That is why the opportunities Acumen highlights, such as broader use of quantitative HBsAg testing, new care pathways that combine patient selection with biomarker monitoring, and approvals in high-burden regions, are really one opportunity seen from different angles. Companies, health systems and patient groups that close the diagnosis gap will shape how close this market comes to its 2035 forecast. You can follow related regulatory developments in our pharmaceutical news coverage, including the FDA’s extended review of Novo Nordisk’s denecimig.
Frequently Asked Questions
How big is the bepirovirsen market?
Acumen Research and Consulting estimates the bepirovirsen market at USD 36.04 million in its 2026 launch year and USD 266.13 million in 2027, growing to USD 2,116.99 million by 2035.
What is the growth rate of the bepirovirsen market?
The market is projected to grow at a CAGR of 29.6% between 2027 and 2035.
Is bepirovirsen FDA approved?
Yes. GSK announced on 20 October 2026 that the FDA approved bepirovirsen, under the brand name Hibsago, for eligible adults with chronic hepatitis B. Japan approved it in August 2026.
What is bepirovirsen used for?
It treats chronic hepatitis B in adults without cirrhosis who have been on nucleos(t)ide analogue therapy for at least six months, have suppressed HBV DNA and have an HBsAg level of 3,000 IU/mL or lower. It is given for six months alongside their existing antiviral.
How effective is bepirovirsen?
In the Phase III B-Well trials, 19% of eligible patients achieved a functional cure, compared with none on placebo. The rate was 26% in patients with baseline HBsAg of 1,000 IU/mL or lower.
Which region leads the bepirovirsen market?
North America leads, with a 73.86% share forecast for 2027. Europe is expected to grow fastest, at a 52.7% CAGR through 2035.
Who makes bepirovirsen?
GSK develops and commercialises bepirovirsen. The drug was discovered by Ionis Pharmaceuticals, and GSK is partnering with Sino Biopharmaceutical in China.
Market figures are drawn from the Bepirovirsen Market report by Acumen Research and Consulting (last updated 23 October 2026). Clinical and regulatory details are based on announcements by GSK and Ionis. This article is for information only and is not medical or investment advice. Patients should discuss treatment options with their doctor.